bioMerieux (OTCMKTS:BMXMF) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of bioMerieux (OTCMKTS:BMXMF) to a hold rating in a research report released on Tuesday morning,Zacks.com reports.

A number of other research firms have also issued reports on BMXMF. Deutsche Bank Aktiengesellschaft lowered bioMerieux from a “buy” rating to a “hold” rating in a report on Friday, April 24th. BNP Paribas Exane cut bioMerieux to a “neutral” rating in a research note on Wednesday, January 28th. Four analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

bioMerieux Price Performance

Shares of OTCMKTS BMXMF remained flat at $77.38 during midday trading on Tuesday. 577 shares of the company were exchanged, compared to its average volume of 204. The stock’s 50 day moving average is $107.96 and its 200-day moving average is $118.41. bioMerieux has a fifty-two week low of $77.38 and a fifty-two week high of $152.00. The company has a quick ratio of 1.48, a current ratio of 2.39 and a debt-to-equity ratio of 0.08.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.